Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

Published:2017-03-16 Issue:6 Volume:19 Page:831-841
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Nyström Thomas¹,Bodegard Johan²,Nathanson David¹,Thuresson Marcus³⁴,Norhammar Anna⁵,Eriksson Jan W.⁶^ORCID

Affiliation:

1. Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Karolinska Institute; Södersjukhuset; Stockholm Sweden

2. AstraZeneca Nordic-Baltic; Södertälje Sweden

3. Cardiology Unit, Department of Medicine, Solna; Karolinska Institute; Stockholm Sweden

4. Capio S:t Görans Hospital; Stockholm Sweden

5. Statisticon AB; Uppsala Sweden

6. Department of Medical Sciences, Clinical Diabetes and Metabolism; Uppsala University; Uppsala Sweden

Funder

AstraZeneca AB

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12889/fullpdf

Reference48 articles.

1. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Inzucchi;Diabetes Care,2012

2. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes;Inzucchi;Diabetes Care,2015

3. Insulin-associated weight gain in diabetes-causes, effects and coping strategies;Russell-Jones;Diabetes Obes Metab,2007

4. Effect of insulin therapy on quality of life in type 2 diabetes mellitus: The Fremantle Diabetes Study;Davis;Diabetes Res Clin Pract,2001

5. Consensus statement by the American Association of Clinical Endocrinologists and American College of endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary;Garber;Endocr Pract,2016

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk;The Lancet Regional Health - Europe;2024-03

2. Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies;Frontiers in Pharmacology;2023-10-13

3. Dapagliflozin ameliorated retinal vascular permeability in diabetic retinopathy rats by suppressing inflammatory factors;Journal of Diabetes and its Complications;2023-10

4. Cardiovascular outcomes of dapagliflozin in type 2 diabetes mellitus in real clinical practice: a meta-analysis of observational studies;Consilium Medicum;2023-08-10

5. Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults;MDM Policy & Practice;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3